Literature DB >> 8389290

Lafora's disease in south India: a clinical, electrophysiologic, and pathologic study.

J N Acharya1, P Satishchandra, T Asha, S K Shankar.   

Abstract

Twenty-one cases (12 males, 9 females) of Lafora's disease in 16 families were studied at the National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India, from 1982 to 1990. Mean age of onset was 13.5 years (range 9.5-18 years). First symptom was generalized tonic-clonic seizure (17), myoclonus (3), or dementia (1). All patients eventually developed the classical triad, except 1 who has had only myoclonus. Seven had occipital seizures. Other signs included behavioral changes (9), brisk tendon reflexes (11), cerebellar signs (8), and visual impairment (4). Patients from 14 of the 16 families (85%) were products of consanguineous marriage. More than 1 sibling was affected in 6 families. Scalp EEGs showed diffuse background slowing with epileptiform discharges in all and progressive slowing as the disease progressed in 3. Photosensitivity occurred in 4 of the 17 cases studied (23.5%). EEG abnormalities were documented in the presymptomatic stage in 2 cases 6 months and 6 years before clinical symptom onset. Visual evoked responses were abnormal in 4 of the 6 cases studied. Giant somatosensory evoked potentials (SSEP) were observed in all 8 cases studied. Lafora bodies were demonstrated in axillary skin in 14 of 17 (82.4%), in liver in 4 of 10 (40%), and in both brain biopsy specimens. In 2 cases, liver biopsy was positive while axillary skin biopsy was negative. In the brain, inclusions were evident in glial and capillary endothelial cells in addition to neurons. Although our cases were similar to those described earlier, the relative rarity of visual phenomena is emphasized. The clinical pattern was consistent with autosomal recessive inheritance. The high frequency of consanguinity in the South Indian population may be responsible for the many cases observed at our center.

Entities:  

Mesh:

Year:  1993        PMID: 8389290     DOI: 10.1111/j.1528-1157.1993.tb02588.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

2.  Diagnosis of Lafora Disease by Skin Biopsy.

Authors:  Prasath Sathiah; Debasis Gochhait; Priyadarshini Dehuri; Hema Subramanian
Journal:  J Clin Diagn Res       Date:  2017-09-01

3.  Malin regulates Wnt signaling pathway through degradation of dishevelled2.

Authors:  Jaiprakash Sharma; Shalaka Mulherkar; Diptendu Mukherjee; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

Review 4.  Advances in lafora progressive myoclonus epilepsy.

Authors:  Antonio V Delgado-Escueta
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

5.  Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.

Authors:  Sudheendra N R Rao; Jaiprakash Sharma; Ranjan Maity; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2009-11-05       Impact factor: 5.157

6.  Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.

Authors:  Jaiprakash Sharma; Diptendu Mukherjee; Sudheendra N R Rao; Soumya Iyengar; Susarla Krishna Shankar; Parthasarathy Satishchandra; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

Review 7.  Links between autophagy and disorders of glycogen metabolism - Perspectives on pathogenesis and possible treatments.

Authors:  Benjamin L Farah; Paul M Yen; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2019-11-21       Impact factor: 4.797

8.  Epilepsy: Indian perspective.

Authors:  Nandanavana Subbareddy Santhosh; Sanjib Sinha; Parthasarathy Satishchandra
Journal:  Ann Indian Acad Neurol       Date:  2014-03       Impact factor: 1.383

Review 9.  Progressive myoclonic epilepsy.

Authors:  Mary L Zupanc; Benjamin Legros
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.